Reuters logo
BRIEF-Mologen AG and Chinese iPharma sign binding term for development of lefitolimod in China
August 25, 2017 / 6:25 PM / 3 months ago

BRIEF-Mologen AG and Chinese iPharma sign binding term for development of lefitolimod in China

Aug 25 (Reuters) - Mologen Ag

* Mologen AG says Co and Chinese iPharma Ltd signed binding term sheet for collaboration regarding development, of lefitolimod in China

* Subject to signing of final documentation, iPharma commits to make an upfront payment of 3 million euros under licence agreement Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below